People taking Zepbound lost 20.2% of their body weight ... Patients received weekly injections of either drug, up to the maximum tolerated dose. The release of the results comes after both Lilly ...

Eli Lilly, opens new tab said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's (NOVOb.CO), opens new tab Wegovy in the first ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. Photo by Pixabay/Pexels Zepbound, the new GLP-1 ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from ...

Eli Lilly’s (LLY) shares rose on Wednesday after the healthcare company announced study results showing that its weight-loss drug Zepbound outperformed Novo Nordisk’s (NVO) Wegovy. On average ...

Shelby Knowles / Bloomberg / Getty Images Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study. Zepbound patients lost an ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

The study results should help fuel Zepbound’s accelerating market-share gains, Leerink Partners analyst David Risinger said in a research note. The drug brought in $1.3 billion in sales for ...

Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

Copyright 2024 The Associated Press. All Rights Reserved. Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Shares of Eli Lilly climbed Wednesday ...